IL2 and Miyoshi myopathy: Patients in the clinical benefit group for MM were more likely to receive a greater number of HD IL-2 doses (33.0 versus 18.0, p =0.001) and a greater number of total cycles (6.0 versus 2.0, p <0.001) than those in the no clinical benefit group.